"Violations of Corporate Integrity Agreement Trigger Divestiture Action by HHS OIG"

by Skadden, Arps, Slate, Meagher & Flom LLP

[authors: John T. Bentivoglio, Jennifer L. Bragg, Michael K. Loucks, Gregory M. Luce, Alexander R. Cohen]

In a little-noticed decision, the Office of the Inspector General of the Department of Health and Human Services (OIG) has forced a company that violated its corporate integrity agreement (CIA) to divest a subsidiary as a condition for the parent to avoid exclusion from federal health care programs. Not only is forced divestiture a relatively new enforcement approach for the OIG, this appears to be the first time the OIG has used forced divestiture as a sanction for violations of a CIA. The move signals the OIG’s continuing willingness to achieve program compliance through novel uses of its enforcement authority. 

Top-Line Summary
  • The HHS OIG recently required a company to divest a business unit in response to the parent’s violation of its corporate integrity agreement — the first time the agency has taken such action.

  • The divestiture action reflects two trends in OIG enforcement policy:  (1) use of divestiture as a sanction for noncompliance and (2) the growing scrutiny of company compliance with CIAs.
  • Companies operating under CIAs should be aware of the use of divestiture as a sanction for serious CIA violations and enhance their CIA compliance efforts accordingly.

Background: Settlement and CIA

Church Street Health Management (CSHM) (formerly FORBA Holdings, Inc.) entered into a civil settlement agreement with the U.S. Department of Justice (DOJ) on January 20, 2010. The DOJ alleged that the company engaged in a pattern of wrongdoing relating to dental services provided to low-income children, including allegations of providing services that were medically unnecessary or failed to meet professionally recognized standards of care.1 As part of the resolution, CSHM paid more than $24 million in penalties and fines and entered into a five-year CIA with the OIG. The CIA contained standard penalty provisions for breaches of the agreement.2

OIG Action for Breaches of the CIA

In March 2012, OIG issued a Notice of Material Breach and Intent to Exclude (Notice) to CSHM. The Notice cited seven CIA provisions — ranging from the requirement to ensure proper and accurate documentation of dental records to management’s certification of compliance — of which CSHM was in material breach. In response, CSHM informed OIG that while the company had taken measures to cure a number of identified breaches, CSHM was unable to resolve certain other breaches within the provided 30-day cure period.

Following a March 13, 2012, meeting, and in apparent recognition of CSHM’s pending bankruptcy proceedings,3 OIG agreed to not commence an exclusion action in exchange for, among other things, (i) CSHM’s agreement to divest, transfer or sell one of its clinics to an unrelated third party within 90 days, and (ii) a waiver of its right to appeal the exclusion.4 On May 30, 2012, with less than two weeks remaining of OIG’s mandated 90-day divesting period, the bankruptcy court overseeing CSHM’s Chapter 11 petition cleared the way for the sale of the clinic.5

OIG’s Program Exclusion Authority   

Considered the death knell for careers and companies alike, the ability to exclude individuals and entities from participating in federal health care programs is perhaps OIG’s most powerful enforcement tool. Excluded providers may not participate either directly or indirectly in Medicare, Medicaid or other federal health programs. Private insurers sometimes prohibit payment to excluded providers. For FY 2011 alone, OIG reported exclusions of 2,662 providers from future participation in federal programs.6

By statute, OIG is authorized to pursue mandatory exclusion (i.e., exclusion by operation of law) (42 U.S.C. § 1320a-7(a)) or permissive exclusion (42 U.S.C. § 1320a-7(b)). For a company operating under a CIA (as in CSHM’s case), exclusion may result from breach of the agreement. Specifically, CSHM’s CIA provides that “[t]he parties agree that a material breach of this CIA by [CSHM] constitutes an independent basis for [CSHM’s] exclusion from participation in the Federal health care programs.”

Forced Divestiture as Alternative to Exclusion   

While exclusion provides OIG with a powerful tool to sanction misconduct, the all-or-nothing nature of exclusion limits its use. The OIG has, understandably, been reluctant to pursue exclusion against organizations due to the potential for collateral consequences against innocent parties, including patients, employees not involved in the misconduct and others. Greg Demske, OIG’s assistant inspector general for legal affairs, has stated that “we can exclude the entity that has been convicted[, but] it’s not as easy to exclude a corporate affiliate.” Not surprisingly, the agency has long sought alternative sanctions that reflect the seriousness of certain types of corporate misconduct but stop short of exclusion. One relatively new approach involves forced divestiture of a business unit.

The first case in which the OIG pursued a forced divestiture occurred in the context of the global resolution of a United States DOJ investigation of Synthes and its U.S. subsidiary, Norian Corporation. According to the government, Synthes and Norian conducted unauthorized clinical trials that ultimately led to several patient deaths. In addition to paying $24 million in criminal and civil penalties, Synthes entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetics Act (FDCA) and entered into a CIA with OIG. Norian pled guilty to various criminal violations, and became subject to mandatory exclusion. In an unprecedented move for health care fraud cases, OIG, Synthes and Norian executed a divestiture agreement.7 Under this agreement, Synthes was required to sell or dissolve Norian within seven months, or face program exclusion.8

Forced Divestiture in the CSHM Settlement   

Much like Synthes’ divestiture of Norian, OIG has called for CSHM to sell Small Smiles Dental Center of Manassas or risk federal health program exclusion.9 The CSHM matter, however, is distinct from Synthes in three main respects. First, CSHM’s forced divestiture arises from noncompliance with the terms of an existing CIA.10 This is the first time in a health care fraud case OIG has used forced divestiture of a company subsidiary to cure deviations from CIA-imposed compliance obligations. Second, the truncated time frame required for the divestiture to occur — a mere 90 days — stands in stark contrast to the seven-month period for Norian’s sale.  As demonstrated by the bankruptcy court’s recent approval of CSHM’s asset sale, operational and practical considerations make completing such a complicated transaction in a condensed time frame challenging. Third, unlike the statutorily based mandatory exclusion used in Norian, the authority for excluding Manassas Center is contractual (i.e. the CIA). As a basis for program exclusion, this authority is weaker and more subject to legal challenge. As a result, OIG required CSHM to waive its appeal rights by agreeing that the Manassas Center “shall be excluded” in the event CSHM does not close or transfer the center within the required period.

Future Implications for Health Care Organizations 

The forced divestiture of a business unit in the context of a company’s alleged breach of its CIA is yet another example of the OIG’s novel use of its enforcement authorities to address perceived misconduct by a health care organization. It is not likely to be the last. Agency officials, for example, have floated the notion of forcing a company to divest a product or product line in order to avoid an exclusion action.11 Using the threat of exclusion to force the divestiture of a business unit or product raises troubling legal and policy issues. Congress has provided the OIG with specific enforcement tools, including civil money penalties and exclusion. Forced divestiture is not among these enumerated sanctions. Perhaps more troubling, the process lacks transparency as the OIG has not issued guidance (much less regulations) as to when it might pursue divestiture. For example, it is not clear why divestiture of a specific clinic was appropriate in the CSHM case given the company’s bankruptcy status and likely changes to its ownership structure. Companies involved in federal health care investigations should be aware of the OIG’s evolving enforcement practices and incorporate such knowledge in developing effective defense strategies.


1 DOJ Press Release, National Dental Management Company Pays $24 Million to Resolve Fraud Allegations, http://www.justice.gov/opa/pr/2010/January/10-civ-052.html (Jan. 20, 2010). 

2 CSHM’s failure to comply with certain obligations contained within the CIA could result in the imposition of stipulated monetary penalties including, for example, a stipulated penalty of $50,000 for each false certification submitted by or on behalf of CSHM. See FORBA Holdings, LLC Corporate Integrity Agreement, pg. 46 (Jan. 15, 2010), available at http://oig.hhs.gov/fraud/cia/agreements/forba_holdings_llc_01152010.pdf.

3 “We understand that CSHM is in the process of closing or transferring the Manassas Center to an unrelated third party.” Amendment to CSHM CIA, pg. 3 (Mar. 14, 2012), available here. On February 20, 2012, CSHM filed in United States Bankruptcy Court for the Middle District of Tennessee a petition for Chapter 11 bankruptcy. CSHM cited the combined cost of its settlement with the government, ongoing CIA compliance and follow-on litigation as the primary causes of its insolvency. In Re: Church Street Health Management, LLC, et al., No. 3:12-01573, (Bankr. M.D. Tenn. Feb. 20, 2012). 

4 Amendment to CSHM CIA, pg. 3 (“In the event CSHM does not close or transfer The Manassas Center as described above, CSHM agrees that the Manassas Center shall be excluded from participation in the Federal health care programs.”). 

5 In Re: Church Street Health Management, LLC, Dkt. 418 (May 30, 2012) (granting CSHM permission to sell assets free and clear of any encumbrances). 

6 OIG Semiannual Report to Congress, http://oig.hhs.gov/reports-and-publications/archives/semiannual/2011/fall/HHS-OIG-SAR-Fall2011.pdf (Fall 2011). 

7  http://www.justice.gov/usao/pae/Pharma-Device/synthes_divestagrmt.pdf

8 For more on the Norian divestiture, see In Forcing Subsidiary Divestiture, OIG Shakes Up Health Care Enforcement, available at http://www.skadden.com/content/Publications/Publications2245_0.pdf (Oct. 6, 2010). 

9 Amendment to Church Street Health Management (fka FORBA Holdings) CIA (available here, March 14, 2012). 

10 FORBA Holdings (d/b/a Church Street Health Management) CIA http://oig.hhs.gov/fraud/cia/agreements/forba_holdings_llc_01152010.pdf (effective Jan. 15, 2010). 

11 Lew Morris, OIG Chief Counsel, Interview on PBS Nightly Business Report (Mar. 18, 2010).

Download PDF Version


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Skadden, Arps, Slate, Meagher & Flom LLP | Attorney Advertising

Written by:

Skadden, Arps, Slate, Meagher & Flom LLP

Skadden, Arps, Slate, Meagher & Flom LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.